IL247084B - dose fgh–18 - Google Patents

dose fgh–18

Info

Publication number
IL247084B
IL247084B IL247084A IL24708416A IL247084B IL 247084 B IL247084 B IL 247084B IL 247084 A IL247084 A IL 247084A IL 24708416 A IL24708416 A IL 24708416A IL 247084 B IL247084 B IL 247084B
Authority
IL
Israel
Prior art keywords
fgh
dosage regimen
regimen
dosage
Prior art date
Application number
IL247084A
Other languages
English (en)
Hebrew (he)
Other versions
IL247084A0 (en
Inventor
Christoph Ladel
Hans Guehring
Original Assignee
Christoph Ladel
Hans Guehring
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christoph Ladel, Hans Guehring, Merck Patent Gmbh filed Critical Christoph Ladel
Publication of IL247084A0 publication Critical patent/IL247084A0/en
Publication of IL247084B publication Critical patent/IL247084B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL247084A 2014-02-20 2016-08-03 dose fgh–18 IL247084B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (2)

Publication Number Publication Date
IL247084A0 IL247084A0 (en) 2016-09-29
IL247084B true IL247084B (en) 2019-09-26

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
IL247084A IL247084B (en) 2014-02-20 2016-08-03 dose fgh–18
IL247083A IL247083B (en) 2014-02-20 2016-08-03 dose fgh–18

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL247083A IL247083B (en) 2014-02-20 2016-08-03 dose fgh–18

Country Status (25)

Country Link
US (2) US9724388B2 (lt)
EP (2) EP3119417B1 (lt)
JP (2) JP6431083B2 (lt)
KR (2) KR102410988B1 (lt)
CN (2) CN106456713A (lt)
AR (2) AR099558A1 (lt)
AU (2) AU2015220773B2 (lt)
BR (2) BR112016018685A2 (lt)
CA (2) CA2938791A1 (lt)
DK (2) DK3107559T3 (lt)
ES (2) ES2688551T3 (lt)
HR (2) HRP20181570T1 (lt)
HU (1) HUE040350T2 (lt)
IL (2) IL247084B (lt)
LT (2) LT3107559T (lt)
MX (2) MX2016010872A (lt)
NZ (2) NZ723139A (lt)
PL (2) PL3119417T3 (lt)
PT (2) PT3119417T (lt)
RS (2) RS57853B1 (lt)
RU (2) RU2700582C2 (lt)
SG (2) SG11201606502YA (lt)
SI (2) SI3119417T1 (lt)
WO (2) WO2015124731A1 (lt)
ZA (2) ZA201605548B (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3107592T (pt) 2014-02-20 2018-12-03 Merck Patent Gmbh Implante que compreende fgf-18
JP6431083B2 (ja) 2014-02-20 2018-11-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18化合物の投与計画
ES2878575T3 (es) 2016-02-22 2021-11-19 Novartis Ag Métodos para usar agonistas del FXR
AU2018343980A1 (en) * 2017-09-29 2020-04-02 Merck Patent Gmbh Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
AU2020218844A1 (en) * 2019-02-08 2021-08-19 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
AU2005269995C1 (en) * 2004-07-06 2011-12-01 Zymogenetics, Inc. Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
WO2007070983A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
JP5815206B2 (ja) * 2006-08-25 2015-11-17 アレス トレーディング ソシエテ アノニム Fgf−18を用いた軟骨障害の治療
RS52710B (en) * 2006-08-25 2013-08-30 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
PT3107592T (pt) 2014-02-20 2018-12-03 Merck Patent Gmbh Implante que compreende fgf-18
NZ723169A (en) 2014-02-20 2023-05-26 Merck Patent Gmbh Fgf-18 in graft transplantation and tissue engineering procedures
JP6431083B2 (ja) 2014-02-20 2018-11-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18化合物の投与計画

Also Published As

Publication number Publication date
IL247083A0 (en) 2016-09-29
KR102410986B1 (ko) 2022-06-17
SI3107559T1 (sl) 2018-11-30
CA2938793A1 (en) 2015-08-27
KR102410988B1 (ko) 2022-06-17
AU2015220777B2 (en) 2020-10-22
ZA201605548B (en) 2018-12-19
DK3119417T3 (en) 2018-10-22
HRP20181572T1 (hr) 2018-11-30
RU2016137289A (ru) 2018-03-21
WO2015124731A1 (en) 2015-08-27
US9724388B2 (en) 2017-08-08
MX2016010871A (es) 2016-11-17
CN106456713A (zh) 2017-02-22
BR112016018685A2 (pt) 2017-10-17
AR099558A1 (es) 2016-08-03
EP3119417B1 (en) 2018-07-11
JP2017512194A (ja) 2017-05-18
AU2015220773B2 (en) 2020-10-08
MX2016010872A (es) 2016-11-17
RU2016137292A (ru) 2018-03-21
ES2688551T3 (es) 2018-11-05
ZA201605547B (en) 2019-09-25
JP6431082B2 (ja) 2018-11-28
RS57709B1 (sr) 2018-12-31
SG11201606502YA (en) 2016-09-29
CA2938791A1 (en) 2015-08-27
AU2015220773A1 (en) 2016-09-01
PL3119417T3 (pl) 2019-01-31
AR099510A1 (es) 2016-07-27
RU2016137292A3 (lt) 2018-09-17
ES2689071T3 (es) 2018-11-08
JP2017507142A (ja) 2017-03-16
NZ723139A (en) 2022-12-23
US9889179B2 (en) 2018-02-13
EP3107559B1 (en) 2018-07-11
US20170072017A1 (en) 2017-03-16
IL247083B (en) 2019-09-26
RU2691946C2 (ru) 2019-06-19
SI3119417T1 (sl) 2018-11-30
RS57853B1 (sr) 2018-12-31
RU2700582C2 (ru) 2019-09-18
WO2015124727A1 (en) 2015-08-27
KR20160116000A (ko) 2016-10-06
HUE040350T2 (hu) 2019-03-28
HRP20181570T1 (hr) 2018-11-30
PT3107559T (pt) 2018-10-31
IL247084A0 (en) 2016-09-29
EP3107559A1 (en) 2016-12-28
AU2015220777A1 (en) 2016-09-01
RU2016137289A3 (lt) 2018-10-19
CN106232622A (zh) 2016-12-14
PL3107559T3 (pl) 2019-01-31
LT3107559T (lt) 2018-10-25
LT3119417T (lt) 2018-10-25
US20170056474A1 (en) 2017-03-02
NZ723148A (en) 2022-08-26
PT3119417T (pt) 2018-10-31
DK3107559T3 (en) 2018-10-15
EP3119417A1 (en) 2017-01-25
JP6431083B2 (ja) 2018-11-28
SG11201606505UA (en) 2016-09-29
BR112016018696A2 (pt) 2017-10-17
KR20160116001A (ko) 2016-10-06

Similar Documents

Publication Publication Date Title
AU356804S (en) Tablet
GB201713653D0 (en) Dosage regimen
AU361269S (en) Package
GB201420208D0 (en) Barrier
FI3363428T3 (fi) Perfuusioannosmuoto
GB201521217D0 (en) Dosage regimens
IL247084B (en) dose fgh–18
PT3152383T (pt) Barreira
ZA201502204B (en) Barrier
GB201420300D0 (en) Tablet
EP3689775C0 (en) PACKAGING
GB201418710D0 (en) Dosage regimen
PL3215437T3 (pl) Urządzenie dozujące
IL266255A (en) New dosage regimen
AU356801S (en) Tablet
HRP20181756T1 (hr) Režim liječenja sa spojem tiakumicina
HRP20181406T1 (hr) Farmaceutski dozni oblici
ZA201800217B (en) Novel dosage regimen tiacumicin compound
GB201617850D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201411345D0 (en) Nicotine dosage regimen
AU356805S (en) Tablet

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed